Massive Bio, a US-based provider of precision medicine and patient centric clinical trial matching services, has announced the launch of its newly developed ‘Hub’.
The new Hub aims to build strategic collaboration with prominent just-in-time (JIT) vendors and clinical research teams, looking to facilitate the JIT oncology clinical trial network in the world.
Massive Bio co-founder and CEO Selin Kurnaz said: “We have been working in ‘stealth mode’ over several months to understand the pros-and-cons of leveraging JIT networks. This analysis resulted in Massive Bio’s ‘Hub’ development, and its key role in managing a series of JIT Oncology Clinical Trial Networks.
“This first-in-class Hub is responsible for evaluating market players in the JIT arena, understanding the needs of pharmaceutical companies, and Contract Research Organizations (CROs), assessing the provider networks interested in opening JIT sites, and further enabling clinical research services to perform the highest patient enrolment potential.”
The global partnership clinical trials network will combine Massive Bio’s new technology and oncology expertise, along with newly developed capabilities from strategic JIT services, to form the world’s largest AI-enabled oncology site network.
The company noted that it has a better enrolment rate due to its focus on oncology and sub-specialist supervision combined with clinical navigation support.
Massive Bio co-founder and chief medical advisor Arturo Loaiza-Bonilla said: “This partnership network offers an unprecedented opportunity to activating our AI enabled precision oncology expertise and patient-centered perspective at a global scale, just where the patient needs it the most, while advancing cancer research.”
Last month, Massive Bio partnered in the Biden Cancer Initiative’s Oncology Clinical Trial Information Commons (OCTIC), aimed at increasing access to oncology clinical trials.